Faculté de Médecine
1, rue Gaston Veil
60 articles with OSE Immunotherapeutics
9/24/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020
Data include significant increase to overall survival and good safety profile in non-small cell lung cancer patients after failure with checkpoint inhibitor therapies
Positive results for Step-1 of Phase 3 clinical trial of Tedopi ® in non-small cell lung cancer Positive preclinical and in human ex vivo results with CoVepiT vaccine against COVID-19; clinical entry expected by the end of 2020 or early 2021 Two Phase 2 clinical trials with OSE-127 planned to start in Q4 2020 in ulcerative colitis and in the Sjögren syndrome Strong progress on BiCKI ® , bi-specific platform, and CLEC-1 antagonist preclinical programs in immuno-oncology €7 million
OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September 14 - 16, 2020 (Virtual Conference)
OSE Immunotherapeutics announced it will present at the H.C. Wainwright 22nd Annual Global Investment Conference.
OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT
Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2targets with technology known to induce memory T lymphocytes
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program
OSE Immunotherapeutics announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.
OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy
Data being presented in two poster presentations at AACR Virtual Meeting II 2020 – June 22-24
OSE Immunotherapeutics Announces Procedures for Virtual Combined General MeetingLive Webcast Login Information
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the procedures for participating in the Combined General Meeting, to be held on June 16, 2020 at 2:30 p.m. CET.
OSE Immunotherapeutics, announced the signature of a €7 million non-dilutive loan agreement, with a pool of French banks, providing the company with further financing to advance its clinical and preclinical development programs.
OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer ImmunotherapyOral Presentation at AACR Virtual Meeting II 2020 – June 22-24
Tumor cells inhibit myeloid cell phagocytosis and dendritic cell antigen presentation through the novel “Don’t eat me” signal mediated by CLEC-1
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients;
OSE Immunotherapeutics Reports 2019 Financial Results and Provides Business Update Expectations for Potential Impact of COVID-19 on the Company’s Clinical Development Activities
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated annual financial results for 2019 and provided an update on key achievements, as well as the company’s outlook for its agonist and antagonist immunotherapies for cancers and autoimmune diseases.
3/19/2020Companies from across the globe provide updates on their business operations and pipeline development.
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) and Servier today announced the execution of an amendment to the two-step global licensing option agreement for exclusive global rights to interleukin-7 receptor (IL-7R) antagonist OSE-127.